Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontline asciminib combination in chronic phase CML
2024-516212-24-00Phase 2Authorised
- Sponsor
- Friedrich Schiller University Jena
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Friedrich Schiller University Jena. Primary endpoint: Rate of MR4 at month 12. Planned start Oct 2024; status: authorised.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-516212-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516212-24-00.